Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 228 participants.
Also called NCT04602754
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 228 participants
- Sponsor
- EMS
- Registry
-
NCT04602754
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Brazil
- Registry status
- Recruiting
Technical summary
Registry record NCT04602754. Randomized; double masking; primary purpose treatment. Start 2023-12-01 (actual); primary completion 2026-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.
- Condition
- Dyslipidemia Associated With Type II Diabetes Mellitus
- Intervention (Drug)
- BERLIM 25/20 ASSOCIATION
- Intervention (Other)
- EMPAGLIFLOZIN PLACEBO
- Intervention (Other)
- ROSUVASTATIN CALCIUM PLACEBO
- Intervention (Drug)
- EMPAGLIFLOZIN
- Intervention (Drug)
- ROSUVASTATIN CALCIUM
- Intervention (Other)
- BERLIM 25/20 ASSOCIATION PLACEBO
- Lead sponsor
- EMS
Record details
- Record id
cardio:ct-nct04602754- Content hash
94de2a8a248710a6758dab73a04b85241c45341298dcdb3b57db4892d0fa8954